Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cstone Pharmaceuticals Co. Ltd.
Industry Sector: HealthTechnology
CEO: Jian Xin Yang, MD, PhD
Number Of Employees: N/A
Enterprise Value: $334,606,354
PE Ratio: -40
Exchange/Ticker 1: HKEX:2616
Exchange/Ticker 2: N/A
Latest Market Cap: $505,429,776
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Jun 1, 2024
Data Byte
EMA’s CHMP recommends new indications for Dupixent, Skyrizi
May decisions also include CStone’s PD-1 inhibitor and Pfizer’s Factor IX gene therapy
BioCentury | Apr 3, 2024
Management Tracks
Takeda vet Tanigaki named CEO of Aculys
Plus: Lonza names Wolfgang Wienand CEO, and updates from Verily, GSK, NewAmsterdam, Voyager, Adaptive, Ratio, Adlai Nortye and I-Mab
BioCentury | Mar 8, 2024
Product Development
Pfizer blends modality tools in new vision for oncology unit
Pharma outlines goals for oncology business as it moves to integrate ADC play Seagen
BioCentury | Jan 6, 2024
Finance
Strong week for VC deals includes Moonwalk launch, cross-border play OnCusp
Plus: Psychedelic play MAPS rebrands as Lykos, HI-Bio raises a series B, and more cash goes to China-based biotechs
BioCentury | May 9, 2023
Deals
May 8 Quick Takes: EQRx reset brings end of China deals, layoffs
Plus: Legend’s $350M raise helps May follow-ons top April tally; ADC deals by Eisai-BlissBio, FibroGen-Fortis; and more
BioCentury | Jan 4, 2023
Deals
Jan. 3 Quick Takes: Gilead, Evoq in lymphatic delivery deal
Plus: Vera dips on postmarket readout and updates from ArriVent, Apnimed, CStone, Legend and more
BioCentury | Nov 10, 2022
Market Access
Changes in U.S. model cast further doubt on EQRx’s goal of ‘radically’ lower pricing
Shift in pipeline will leave biotech with ‘revenue gap,’ leading to more traditional ‘market-based’ pricing
BioCentury | Aug 26, 2022
Management Tracks
Leading China biotechs Everest, CStone announce CEO departures
Plus updates from BD, Sema4,
BioCentury | Aug 10, 2022
Data Byte
Valuing ADC licensing deals
As data roll in for clinical ADCs licensed since 2020, upfront payments for preclinical deals show signs of growth
Items per page:
1 - 10 of 98